EIK1001

Phase 3Small molecule

EIK1001 is one of 85 small molecule programs targeting Non Small Cell Lung Cancer (Squamous or Non Squamous). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non Small Cell Lung Cancer (squamous or Non Squamous)Recruiting

PembrolizumabRecruiting

MelanomaRecruiting

Non Small Cell Lung Cancer (squamous or Non Squamous)Preclinical

Recruiting

PembrolizumabPhase 2

Recruiting

MelanomaPhase 3

Recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

95 2

Opdivo

Mekinist

45 4

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

39 5

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 6

Taxol

Teva

Phase 3

13 7

Tecentriq

Roche

Phase 3

11 8

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

28 9

Lenvima

Eisai

Phase 3

9 10

Libtayo

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Pembrolizumab

NCT06246110

Q4 2040

Phase 2/3Recruiting

Melanoma

NCT06697301

PreclinicalRecruiting

Non Small Cell Lung Cancer (squamous or Non Squamous)

NCT07365319

Clinical

Trials by Indication[1]

Melanoma1 trial

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Recruiting·EEikon Therapeutics·Phase 2/3·NCT06697301·740 enrolled

Pembrolizumab1 trial

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Recruiting·EEikon Therapeutics·Phase 2·NCT06246110·70 enrolled

Non Small Cell Lung Cancer (Squamous or Non Squamous)1 trial

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

Recruiting·EEikon Therapeutics·Preclinical·NCT07365319·750 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for EIK1001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EIK1001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EIK1001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eikon Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEikon Therapeutics

EIK1001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2040

Trials by Indication[1]

Melanoma1 trial

Pembrolizumab1 trial

Non Small Cell Lung Cancer (Squamous or Non Squamous)1 trial

References

Drug Info

Quick Facts

Related News